Q-omics provides the consensus-scored FAM218BP profile across patient tissues and cancer cell-line models. FAM218BP expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, FAM218BP is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, FAM218BP RNA expression shows 6,337 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, COAD, and STAD as cancer lineages where FAM218BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM218BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM218BP survival associations across molecular data types. FAM218BP RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM218BP RNA expression–survival associations across cancer types. High FAM218BP expression shows unfavorable associations in THCA, CESC, GBM and SARC, but favorable associations in ESCA and OV. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for FAM218BP RNA expression.
This table summarizes FAM218BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM218BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM218BP shows lower tumor expression in COAD. The COAD box plot shows higher FAM218BP RNA expression in normal versus tumor tissue (log2 FC = −0.037, t-test p = .034).
This table shows molecular features associated with FAM218BP in patient tissues and cancer cell lines. In patient samples, FAM218BP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
